Octrizole (UV-329) is used as UV stabilizer within products to increase stability to light. It protects polymers as well as organic pigments from UV radiation helping to preserve the original appearance and physical integrity of polymeric systems; particularly in polyesters, polyvinyl chlorides, styrenics, acrylics, polycarbonates and polyvinyl butyral during outdoor weathering. Octrizole is an indirect additive used in food contact substances. It is used in cosmetics. The use levels of Octrizole (UV-329) range between 0.10 and 1.0%, depending on substrate and performance requirements of the final application. The product can be used alone or in combination with other additives such as light stabilizers (hindered amines), antioxidants (hindered phenols, phosphites, thiosynergists, hydroxylamines, benzofuranones), and other functional stabilizers and additives. The use of UV-329 in combination with hindered amine light stabilizers is particularly noteworthy in that a synergistic performance is often observed. Performance data of UV- 329 alone or in combination with other additives are available in selected substrates.

Suxethonium is a depolarising muscle relaxant, with low incidence of postoperative muscle pain.

Darenzepine is an antagonist of muscarinic receptors, developed by at Knoll/BASF Pharma. It is claimed to have antiulcer effect superior to pirenzepine and to have less anticholinergic adverse effects.

ISOPROPICILLIN is semisynthetic penicillin.

Cypothrin is a synthetic pyrethroid insecticide, developed by American Cyanamide for the control of ticks and marketed under the tradename Panecto. The compound exhibited systemic insecticidal activity in the model of flies infestation in mice and ixodicidal activity in against larvae of Boophilus microplus.

Amicus Therapeutics was investigating afegostat (isofagomine; Plicera; HGT-3410; AT-2101), an orally available pharmacological chaperone molecule, which binds to glucocerebrosidase (Gba) and stimulates proper folding and trafficking of the enzyme, for the potential treatment of Parkinsons disease(PD) and Gaucher disease. Afegostat specifically and reversibly binds GCase in the ER with highaffinity; this stabilizes the active form of the enzyme in the ER and increases trafficking of GCase to lysosomes. In 2006, Orphan Drug designations were granted in the U.S. and E.U. in 2006 and 2007, respectively. However, this research has been discontinued.

Murocainide is aminoalkoxybenzofuran derivative patented by pharmaceutical company Delalande S. A. for ventricular tachycardia treatment. At 5 mg/kg i.v. in dogs Murocainide reversed ouabain-induced ventricular tachycardia.

Boehringer Ingelheim developed samixogrel as thromboxane A2 receptor antagonists. This drug participated in clinical trials for the treatment patients with diabetic complications, thrombosis, and unstable angina pectoris. However, all these studies were discontinued.

Piperamide is substituted piperazine with a tertiary amine group. It was used as an anthelmintic agent. Initially, it was investigated because of its effectiveness against Trypanosoma. Piperamide distorts choroid plexus epithelial ultrastructure by engendering hydropic vacuoles.

Meglitinide (HB 699) is an antidiabetic compound. Meglitinide is a short-acting insulin secretagogue that targets one of the main defects that characterizes type 2 diabetes: the progressive loss of early phase prandial insulin secretion. It acts in a glucose-dependent manner to close adenosine triphosphate (ATP)-dependent potassium channels on the β-cell membrane, depolarize the β-cell, resulting in the opening of calcium channels, increased calcium influx and insulin secretion.